Amphastar Pharmaceuticals (AMPH) vs GH Research (GHRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
GH Research (GHRS) has outperformed Amphastar Pharmaceuticals (AMPH) over the past year, gaining 25.1% versus a gain of 8.6%. Over five years, AMPH leads with a +41.9% price change compared with -21.0% for GHRS. Amphastar Pharmaceuticals is the larger company by market cap ($1.20 billion vs $1.20 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMPH | GHRS |
|---|---|---|
| Share price | $28.25 | $17.53 |
| Market cap | $1.20B | $1.20B |
| 1-day change | +0.50% | -5.55% |
| YTD return | +5.49% | +38.03% |
| 1-year return | +8.61% | +25.08% |
| 5-year return | +41.89% | -21.00% |
| P/E ratio (TTM) | 12.96 | — |
| Forward P/E | 8.43 | — |
| EPS (TTM) | $2.18 | $-0.94 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $719.89M | — |
| Revenue growth (YoY) | -1.65% | — |
| Net income (latest FY) | $98.09M | $-48.26M |
| Gross margin | 49.46% | — |
| Operating margin | 19.50% | — |
| Net margin | 13.63% | — |
| 52-week high | $31.00 | $31.44 |
| 52-week low | $16.65 | $12.04 |
| Distance from 52-week high | -8.87% | -44.24% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | -13.27% | +144.67% |
| Average volume | 475.35K | 294.69K |
| Shares outstanding | 42.65M | 68.68M |
| Employees | 1,976 | 73 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GHRS has outperformed AMPH by 16.5 percentage points over the past year.
About Amphastar Pharmaceuticals
AMPH stock →Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,976 employees
About GH Research
GHRS stock →GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression.
Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees
AMPH vs GHRS FAQ
Which is bigger, Amphastar Pharmaceuticals or GH Research?
Amphastar Pharmaceuticals (AMPH) is larger, with a market capitalization of $1.20B compared with $1.20B for GH Research (GHRS).
Which stock has performed better over the past year, AMPH or GHRS?
GHRS returned +25.08% over the past 12 months, compared with +8.61% for AMPH (price return, excluding dividends). Past performance does not predict future results.
Are Amphastar Pharmaceuticals and GH Research in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.